ArticleBiomarker insights2008
What is New on Thyroid Cancer Biomarkers.
Article in Biomarker insights, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers.Diagnostics (Basel, Switzerland) · 2022Review
- Updated Incidence of Thyroid Cancer in the North East Region of Romania after 35 Years of Chernobyl Fallout. Is There a Link between?Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2020Article
- Novel treatments for anaplastic thyroid carcinoma.Gland surgery · 2020Review
- A robust fuzzy rule based integrative feature selection strategy for gene expression data in TCGA.BMC medical genomics · 2019Article
- Methylation markers differentiate thyroid cancer from benign nodules.Journal of endocrinological investigation · 2018Article
- Differentiating malignant from benign thyroid nodules with indeterminate cytology byScientific reports · 2017Article
- Hepatocyte Growth Factor/C-Met Axis in Thyroid Cancer: From Diagnostic Biomarker to Therapeutic Target.Biomarker insights · 2017Review
- HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.International journal of molecular sciences · 2016Article
- Etiopathogenesis of Differentiated Thyroid Carcinomas.Open access Macedonian journal of medical sciences · 2016Review
- Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Targeted oncology · 2016Article
- Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes.Cancer and clinical oncology · 2015Article
- Personalization of targeted therapy in advanced thyroid cancer.Current genomics · 2014Article
- Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.International journal of endocrinology · 2014Review
- Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.Virchows Archiv : an international journal of pathology · 2013Article
- Developing organized level of biomedical evidence: evidence-based biomedicine.Frontiers in physiology · 2012Article
- DNA methylation in thyroid tumorigenesis.Cancers · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer harbours in about 5% of thyroid nodules. The majority of them are well-differentiated cancers originating from the follicular epithelium, and are subdivided into papillary and follicular carcinomas. Undifferentiated carcinomas and medullary thyroid carcinomas arising from C cells are less common.Although most thyroid nodules are benign, distinguishing thyroid cancer from benign lesions is crucial for an appropriate treatment and follow-up. The fine needle aspiration cytology (FNAC) allows the diagnosis of nature of thyroid nodules in the majority of cases. However, FNAC has some limitations, particularly in the presence of follicular lesions which can appear dubious in rare instances even at histology.In an effort to improve diagnostic accuracy and offer new prognostic criteria, several immunohistochemical and molecular markers have been proposed. However, most of them have to be validated on large series before being used in routine practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.